Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 risankizumab study in moderate to severe hidradenitis suppurativa
NL-OMON50087Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: HiSCR at Week 16. Started Jan 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON50087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50087.